A Phase 1 interventional study of DSP-1349M and placebo in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-05-08.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 28th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 1, and was the 36th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2018.
This study's enrollment of 40 is below the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 30th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2018, is one of 11 in phase 1, and was the 34th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia
This is a single-center, randomized, double-blind, placebo-controlled, inpatient, single ascending dose (SAD) study designed to evaluate the safety, tolerability, and PK of lurasidone injectable suspension in subjects with schizophrenia. This study will determine the minimum intolerable dose (MID), the maximum tolerated dose (MTD) of lurasidone injectable suspension, and characterize the PK profiles of lurasidone and its metabolites in serum (ID-14283, ID-14326, ID-11614, ID-20219, and ID-20220) and urine (ID-14283, ID-14326, and ID-11614) in this subject population. The potential effects of gender on the PK of lurasidone injectable suspension and its metabolites will also be evaluated when applicable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has capacity; is willing and able to provide written consent for use and disclosure of protected health information per requirements of 45CFR164.508 (Health Insurance Portability and Accountability Act; HIPAA) prior to initiating any study procedure after being informed of the nature of the study, in the opinion of the study staff and PI.
a. Non- (ie, physiologically incapable of becoming pregnant, including any female who is pre-menarchal or );
Women who have had a hysterectomy, bilateral oophorectomy or bilateral salpingectomy (as determined by subject's medical history).
b. Child-bearing potential (all females ≤ 65 years of age), has a negative pregnancy test at screening and agrees to satisfy one of the following requirements:
Established use of highly effective methods of contraception from 1 month prior to administration of the first dose of study drug, during the Treatment Period, and 60 days after completion or premature discontinuation from the study drug.
Because of the unacceptable failure rate of barrier (chemical and/or physical) methods, the barrier method of contraception must only be used in combination with a highly effective method. Post-coital methods of contraception are not permitted.
Exclusion Criteria:
Subject has positive test results within 28 days prior to the start of the study for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurasidone injection suspension (30 mg, 75 mg, 150 mg, 300 mg, and 450 mg)
Drug: DSP-1349M
placebo injection
Drug: placebo
DSP-1349M injectable
Also known as: lurasidone
placebo injection
Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation
Number of subjects with any Adverse Events (AEs), serious adverse events (SAEs), and Adverse Events (AEs ) leading to study discontinuation
Time frame: Day 61
Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration
The maximum Serum Concentration \[Cmax\] for lurasidone after lurasidone injectable suspension administration
Time frame: Day 61
Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration
The area Under the Curve from time 0 to time of last quantifiable concentration \[AUC0-last\] for lurasidone after lurasidone injectable suspension administration
Time frame: Day 61
| Milestone | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 10 |
| Completed | 5 | 6 | 6 | 6 | 6 | 10 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other (lack of efficacy) | 1 | 0 | 0 | 0 | 0 | 0 |
Number of subjects with any Adverse Events (AEs), serious adverse events (SAEs), and Adverse Events (AEs ) leading to study discontinuation
| count of participants | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo |
|---|---|---|---|---|---|---|
| Incidence of AEs | 4 | 4 | 2 | 4 | 5 | 5 |
| Incidence of SAEs | 0 | 0 | 0 | 0 | 0 | 0 |
| Incidence of AEs leading to study discontinuation | 0 | 0 | 0 | 0 | 0 | 0 |
The maximum Serum Concentration \[Cmax\] for lurasidone after lurasidone injectable suspension administration
| ng/mL | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo |
|---|---|---|---|---|---|---|
| Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration | 1.08 ± 65.6 | 3.90 ± 51.6 | 5.08 ± 46.5 | 8.85 ± 62.8 | 9.50 ± 48.3 | 0 ± 0 |
The area Under the Curve from time 0 to time of last quantifiable concentration \[AUC0-last\] for lurasidone after lurasidone injectable suspension administration
| ng*h/mL | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo |
|---|---|---|---|---|---|---|
| Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration | 628 ± 54.7 | 2000 ± 6.6 | 3540 ± 26.0 | 4910 ± 47.9 | 7490 ± 32.6 | 0 ± 0 |
Collected over 61 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone 30 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Lurasidone 75 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Lurasidone 150 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Lurasidone 300 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Lurasidone 450 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Placebo | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Event | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/6 | 0/6 | 0/6 | 0/6 | 4/6 | 1/10 |
| Injection site reactionGeneral disorders | 0/6 | 0/6 | 1/6 | 2/6 | 3/6 | 1/10 |
| Skin abrasionInjury, poisoning and procedural complications | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 0/10 |
| Weight increasedInvestigations | 0/6 | 0/6 | 2/6 | 0/6 | 1/6 | 2/10 |
| SomnolenceNervous system disorders | 0/6 | 1/6 | 1/6 | 0/6 | 0/6 | 2/10 |
| Ear painEar and labyrinth disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/10 |
| Vision blurredEye disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 |
| Abdominal pain lowerGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 |
| ConstipationGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/10 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/10 |
| Age, Categorical(Participants) | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 6 | 6 | 6 | 10 | 40 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(Years) | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 43.7 ± 13.29 | 45 ± 10.22 | 52 ± 4.47 | 46.2 ± 9.72 | 52.8 ± 11.81 | 45.7 ± 10.25 | 47.4 ± 10.23 |
| Sex: Female, Male(Participants) | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 2 | 2 | 1 | 5 | 15 |
| Male | 3 | 4 | 4 | 4 | 5 | 5 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 | 0 | 2 | 6 |
| Not Hispanic or Latino | 5 | 5 | 6 | 4 | 6 | 8 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 5 | 4 | 5 | 4 | 4 | 7 | 29 |
| White | 1 | 2 | 1 | 1 | 2 | 3 | 10 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Height (cm)(cm) | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 170 ± 8.83 | 173.2 ± 8.61 | 174.3 ± 10.39 | 166.3 ± 7.92 | 174.2 ± 7.25 | 168.5 ± 7.07 | 170.8 ± 8.29 |
| Weight (kg)(kg) | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 88.3 ± 13.53 | 80.3 ± 10.86 | 84.8 ± 21.84 | 82 ± 16.55 | 86.8 ± 15.2 | 86.7 ± 15.07 | 85 ± 14.99 |
| BMI (kg/m^2)(kg/m^2) | Lurasidone 30 mg | Lurasidone 75 mg | Lurasidone 150 mg | Lurasidone 300 mg | Lurasidone 450 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 30.88 ± 6.444 | 27.1 ± 5.522 | 27.68 ± 5.975 | 29.83 ± 6.493 | 28.77 ± 5.125 | 30.37 ± 3.919 | 29.23 ± 5.295 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Mar 2019, 9 months.
Results were first posted in May 2020, 1 year 1 month after primary completion.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 9 months is close to that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →